ACTRIMS Forum 2024 Curated eBook
A curated eBook featuring ACTRIMS studies, findings, and expert opinions.
Apr 12, 2024
Search
Advertisement
MEETING BRIEF
AAO 2023: Retinal Vascular Disease
The latest news from AAO 2023 on retinal vascular disease, including abstracts, featured articles, and information about the conference.
Curated AAO 2023: Retinal Vascular Disease eBook
Curated AAO 2023: Retinal Vascular Disease eBook
A curated eBook featuring AAO 2023: Retinal Vascular Disease-focused studies, findings, and expert opinions.
Inherited Retinal Diseases Often Involve Complex “Diagnostic Odyssey”
Inherited Retinal Diseases Often Involve Complex “Diagnostic Odyssey”
Patients with rare inherited retinal diseases often must undertake a diagnostic odyssey before receiving a correct diagnosis.
Depression Impacts Outcomes in Age-Related Macular Degeneration
Depression Impacts Outcomes in Age-Related Macular Degeneration
In age-related macular degeneration, depression can directly impact patient care through loss to follow-up, cancellations, and lack of treatment adherence.
Minorities Remain Underrepresented in DME Clinical Trials
Minorities Remain Underrepresented in DME Clinical Trials
Many barriers exist in the recruitment for diabetic macular edema clinical trials of patients of minority racial and ethnic backgrounds.
Advertisement
PW QUIZ
Advertisement
Aflibercept 8 Mg Improves Visual Acuity in Diabetic Macular Edema
Aflibercept 8 Mg Improves Visual Acuity in Diabetic Macular Edema
Aflibercept 8 mg shows efficacy for patients with diabetic macular edema regardless of sex, age, and race/ethnicity.
Birdshot Chorioretinopathy Shows Fractal Changes in the Retinal Vascular Layers
Birdshot Chorioretinopathy Shows Fractal Changes in the Retinal Vascular Layers
Fractal dimensions represent a promising biomarker for assessing retinal vascular damage.
Evaluating Efficacy of 8 mg Intravitreal Aflibercept After 48 Weeks for DME Based on Baseline Demographics
Evaluating Efficacy of 8 mg Intravitreal Aflibercept After 48 Weeks for DME Based on Baseline Demographics
The following is a summary of “Intravitreal Aflibercept 8 mg for DME: Week 48 Efficacy Outcomes...
AI Risk Scoring Model for Referable DR Prediction
AI Risk Scoring Model for Referable DR Prediction
The following is a summary of “A Multimodal AI Risk Scoring Model to Predict the Development of...
Subgroup Analyses of Aflibercept 8-mg Intravitreal Injection for nAMD Patients: Phase 3 PULSAR Trial
Subgroup Analyses of Aflibercept 8-mg Intravitreal Injection for nAMD Patients: Phase 3 PULSAR Trial
The following is a summary of “Intravitreal Aflibercept 8-mg Injection in Patients With nAMD:...
Explore, Connect, & Learn at the AAO 2023 Expo
Explore, Connect, & Learn at the AAO 2023 Expo
Explore, connect, learn, relax and more at the AAO 2023 Expo. Follow PW for conference updates.
EXPLORE MORE
AAO Announces The Orbital 2023: Gold Rush Fundraising Event
AAO Announces The Orbital 2023: Gold Rush Fundraising Event, formerly the Orbital Gala.
Virtual Conference
AAO 2023 is offering a virtual version of their conference. Follow PW for conference highlights.
Analysis of Follow-up Traits in an Extensive Diabetes Teleretinal Screening Program
The following is a summary of “Follow-Up Characteristics in a Large Diabetic Teleretinal...
Patients With Retinal Vascular Disease More Prone to Dementia
People with retinal vascular disease, especially central retinal vein occlusion (RVO), are more likely to develop dementia.
Advertisement
Stay connected to the latest news with Physician’s Weekly
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
